VRK2 Inhibition With PD-1 Blockade for Resistant Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The molecular pathways engaged by the checkpoint PD-1 remain poorly defined, limiting the development of effective therapeutics targeting the PD-1 axis, and many patients do not respond to PD-1 blockade, leading to inflammatory toxicities and reduced anti-tumor immunity.
Innovation Solution
Inhibiting Vaccinia Related Kinase 2 (VRK2) in combination with PD-1 blockade enhances T cell activation and augments anti-tumor immune responses, using VRK2 inhibitors such as AZD-7762, IC-261, siRNA, or shRNA to target VRK2, and administering them before, during, or after PD-1 blockade.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1 blockade is administered to enhance anti-tumor immunity, then T cell activation is improved, but inflammatory toxicities increase and response rate is limited
Solution Approach 1:
The invention segments the PD-1 signaling pathway into two distinct targets: PD-1 receptor itself and VRK2 kinase downstream in the pathway. By administering both anti-PD-1 antibody and VRK2 inhibitor, the treatment divides the inhibitory effect across multiple molecular targets, achieving more complete pathway blockade while distributing the therapeutic effect to reduce toxicities.
Solution Approach 2:
The invention changes the molecular parameters of PD-1 signaling by introducing VRK2 inhibition alongside PD-1 blockade. This dual approach modifies the signaling pathway at multiple points, altering the phosphorylation status of downstream substrates and achieving enhanced T cell activation with reduced inflammatory responses compared to PD-1 blockade alone.
2Productivity
If PD-1 blockade is administered to treat neoplasia, then tumor clearance is improved, but resistance develops reducing effectiveness
Solution Approach 1:
The invention segments the therapeutic approach by targeting both PD-1 and VRK2 simultaneously. This multi-target strategy prevents resistance development that occurs with single-target PD-1 blockade, as tumors cannot develop resistance to both targets through a single mechanism, thereby maintaining consistent therapeutic effectiveness.
Solution Approach 2:
The invention uses a composite therapeutic approach combining anti-PD-1 antibody and VRK2 inhibitor. This composite treatment targets multiple components of the PD-1 signaling pathway, creating a synergistic effect that enhances tumor clearance and prevents resistance mechanisms that would limit the effectiveness of monotherapy.
3Reliability
If VRK2 inhibition is added to PD-1 blockade to enhance T cell activation, then anti-tumor immunity is improved, but treatment complexity increases
Solution Approach 1:
The invention extracts VRK2, a downstream component of the PD-1 signaling pathway, as a separate therapeutic target. By isolating and targeting VRK2 with specific inhibitors alongside anti-PD-1 antibody, the treatment enhances T cell activation through coordinated blockade of the pathway at multiple points, achieving synergistic effect while managing treatment complexity.
Data Source
AI summary
Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.